Mathurin P

9 publications in the catalogue · 2011–2022

9 publications

Diseases

  1. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  2. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021

    LCR1 LCR2 HCV

  3. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019

    NashTest-2 SteatoTest-2 Metabolic

  4. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018

    FibroTest NashTest SteatoTest Metabolic

  5. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018

    ActiTest FibroTest NashTest NashTest-2 +3

  6. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017

    FibroTest Alcohol

  7. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012

    ActiTest FibroTest NashTest SteatoTest +1

  8. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011

    FibroTest Metabolic

  9. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011

    FibroTest NashTest SteatoTest Metabolic